Identification of a persistent Ascaris-derived Kalirin epitope associated with chronic T cell activation in the lung Authors: Yifan Wu, Leroy Versteeg, Meng-Chih Wu, Jill E. Weatherhead, Bruce Rosa, Bruce Rosa, Bruce Rosa, Bruce Rosa Published: 2026 ABSTRACT Ascariasis remains a dominant global health burden due to its vast prevalence and associated morbidity. The obligatory migration of Ascaris larvae through pulmonary tissue triggers intense type-2 inflammation which typically presents as acute allergic airway disease. Even after the parasite is eliminated, a single episode of larval migration can result in chronic lung damage and dysfunction, which may be driven by the long-term retention of helminth antigens in macrophages. However, the molecular identity of these retained antigens, and the mechanisms by which they sustain chronic T cell responses, remain unknown. In this study, we utilized immunopeptidomics to identify a retained peptide specific from Ascaris that is sequestered and presented by pulmonary macrophages via MHC-II. We further demonstrated that this retained peptide serves as an epitope which is associated with the development of specific T helper cell populations that persist long after the infection has cleared. These findings define a potential molecular mechanism for persistent helminth-induced immune cell activiation in the lungs and identify a retained epitope as a potential contributor to the development of chronic pulmonary inflammation following parasite elimination from the lungs. Introduction With an estimated 500 million people affected, primarily within low- and middle-income countries, ascariasis represents the most prevalent helminthic infection worldwide. This disease imposes a staggering global burden, resulting in approximately 800,000 disability-adjusted life years lost to morbidity [1–3]. In endemic settings, infection begins in early infancy and continues throughout childhood as a series of recurrent infections [4, 5]. Transmission occurs through the accidental ingestion of Ascaris lumbricoides or Ascaris suum eggs, which are widespread in the environment. Following ingestion, the larvae emerge in the gastrointestinal tract and utilize the circulatory system to migrate through the liver and into the pulmonary tissues. Within the lungs, the larvae traverse the vascular endothelium to enter the parenchyma for further maturation. They eventually migrate across the alveolar surface, ascend the respiratory tract, and are swallowed to reach their final niche in the small intestine [6–8]. This intricate, two-month migratory phase is a physiological requirement for the development of mature adult worms [9]. In the acute phase, the migration of Ascaris larvae through the pulmonary tissues triggers the rapid onset of type-2 inflammation and allergic airway disease. Experimental mouse models demonstrate that the transit of Ascaris larvae incites a robust recruitment of type-2 inflammatory cells, characterized by elevated cytokine production, significant airway hyperreactivity, and excessive mucus secretion. While this aggressive immunological recruitment is functionally intended to constrain larval development and limit the total parasite burden, its immediate clinical result is a period of transient, yet severe, allergic inflammation [10]. Additionally, Ascaris larvae migration incites enduring pathological changes that extend far beyond the acute phase of infection. In experimental mouse model, Ascaris larvae are cleared from the host within 14 days post infection through the intestines [11]. We have previously demonstrated that even a solitary exposure to Ascaris spp. can precipitate chronic lung disease in murine models months after infection resolution, manifesting as both persistent type-2 inflammatory pathology and emphysema-like structural remodeling [12]. Notably, this chronic state is characterized by heightened vascular permeability and the development of systemic anemia that persists for months following the resolution of the primary infection [12]. While prior investigations suggested that sequestered helminth antigens might drive these long-term sequelae [13], the precise molecular identity of these signals and the pathways by which they maintain T cell activation have remained elusive. In the present study, we utilized immunopeptidomics to identify a specific retained peptide derived from the parasite that is continuously presented by MHC class II on pulmonary macrophages to the adaptive immune system. This persistent antigenic signal maintains the activity of epitope-specific T cells, providing a clear molecular link between initial infection and chronic inflammatory pathology. Identification of this retained epitope establishes a potential molecular basis for the chronicity of Ascaris-induced disease and highlights a specific target for future therapeutic intervention. Results Immunopeptidomics identifies a specific Ascaris peptide retained in the lung Our investigation into the specific molecular signatures retained in the lung was informed by the findings of Oliveira et al. [13]. This study demonstrated that Ascaris larval migration leaves behind long-lasting parasite antigens sequestered within the lung parenchyma, and specifically within pulmonary macrophage cytoplasm, which provide a continuous source of immune stimulation even after physical parasite clearance. Because pulmonary macrophages are the specialized phagocytes responsible for the uptake and long-term sequestration of such parasite-derived products, we identified them as the most likely cellular reservoir for these persistent peptides. Briefly, mice were infected with a standard inoculum of 2,500 Ascaris suum eggs via oral gavage. One month after infection, mice were euthanized and lung tissue was harvested. Total pulmonary macrophages were isolated using F4/80 magnetic beads and the cell lysate was prepared (Fig 1A). To identify peptides presented by these isolated macrophages, immunoaffinity purification of the Major Histocompatibility Complex (MHC) class II, which primarily presents peptides derived from extracellular sources, was performed. Purified MHC class II proteins were denatured to release the bound peptides, which were then purified and concentrated. Finally, the collected peptide repertoire was analyzed via Liquid Chromatography-Mass Spectrometry (LC-MS) to identify the retained peptide (Fig 1A). Identification of retained Ascaris epitopes in the lung post-infection. (A) Schematic of experimental design and immunopeptidomic workflow. (B) Length distribution of all 57 peptides identified presented by MHC-II. (C) Tandem mass spectrometry fragmentation spectrum of the retained peptide ETLLFTAVGRKPE. (D) Peptide identification information provided by Fragpipe analysis. (Fig 1A created in BioRender. Poveda, C. (2026) https://BioRender.com/d81rzs7). Immunopeptidomics analysis using proteomes from mouse and Ascaris revealed 57 unique peptide presented by MHC class II on pulmonary macrophages (Fig 1A, S1 Table). While the majority of the peptides were derived from the murine host itself, and several peptides existed in proteins from both murine host and Ascaris, one single peptide unique to Ascaris was identified: ETLLFTAVGRKPE, which is clearly evidenced by the MS/MS fragmentation spectrum (Fig 1B, 1C). Bioinformatic analysis confirmed that this 13-aa peptide is a fragment of the protein Kalirin (Fig 1C, 1D). Kalirin is a Rho guanine nucleotide exchange factor (RhoGEF) that facilitates the transition of small Rho GTPases from an inactive guanosine diphosphate (GDP)-bound state to an active guanosine triphosphate (GTP)-bound state [14]. This transition initiates downstream cascades that regulate the actin cytoskeleton, vesicular trafficking, and neuroendocrine signaling [14, 15]. Notably, this specific sequence is uniquely conserved within Ascaris spp., Parascaris univalens, and Toxocara canis, but is entirely absent from the host proteome. The discovery of this unique Kalirin-derived peptide represents the first identification of a specific Ascaris peptide that remains sequestered within pulmonary macrophages long after the clearance of the primary infection. Immunohistochemistry confirms the sequestration of the retained peptide in pulmonary macrophages To verify the presence of the Kalirin-derived retained peptide within the lungs post Ascaris clearance, we developed a custom polyclonal antibody against the peptide and performed immunohistochemistry (IHC) on lung sections from mice 1 months post infection. We observed notable DAB-positive staining adjacent to the alveolar tissue in the lungs of infected mice (Fig 2A) which was entirely absent in the naïve controls (Fig 2B). Quantification of IHC images revealed that 2.36% of the total lung area was positive for the Kalirin-derived peptide, with the highest density signal localized to the bronchovascular bundle (BVB). Notably, we identified both alveolar and interstitial macrophages containing the retained peptide localized in the alveoli or around the BVB, indicated by the red arrows. This spatial confirmation demonstrates that the retained peptide is specifically sequestered within the pulmonary macrophage niche long after the physical parasite has been eliminated. Validation of retained Ascaris epitopes in the lung post-infection. Immunohistochemistry was carried out using customized polyclonal antibody against retained epitope on (A) lungs from mice 1 month post infection compared to (B) naïve control. Black arrows annotate regions selected for higher magnification, while red arrows indicate epitope-positive pulmonary macrophages. (Magnification: 100× and 400 × . Scale bar: 100μm and 50μm. Data are shown as representative of two independent experiments.). The retained peptide serves as epitope to maintain a specific CD4+ T cell population post-clearance To determine if the Kalirin-derived retained peptide contributes to chronic T cell activation as an epitope after Ascaris clearance, we developed a custom MHC class II tetramer loaded with the peptide. We then performed flow cytometric analysis to identify CD4 + T cells specifically reactive to the retained peptide as epitope in mice one month post-infection. Our analysis revealed a distinct, albeit rare, population of epitope-specific CD4+ T cells in both the lungs and the spleen (Fig 3A–3C). These findings demonstrate that the retained epitope serves as a persistent antigenic stimulus that maintains a dedicated T cell repertoire both in the lungs and systemically in the host despite resolution of the initial infection. Identification of epitope-specific CD4 + T cells in the lungs. Flow cytometric analysis on live CD45+ CD3+ CD4+ T helper cell that binds to MHC class II tetramer holding the retained epitope. Mean±S.E.M for lungs: 0.7100‰ ± 0.3201, 5.500‰ ± 0.119; for spleen: 0.08713‰ ± 0.02978, 0.2800‰ ± 0.07083) (A) Representative flow cytometry gating strategy for MHC class II tetramer. (B-C) Permillage and absolute number of tetramer positive T helper cells in (B) the lungs and (C) the spleen. (n = 4, mean±S.E.M, *p < 0.05, **p < 0.01, using two-tailed Student’s t-test. Data are shown as representative of two independent experiments.). Discussion Here, we provide the first evidence of a specific retained epitope from Ascaris that significantly outlasts the physical presence of the parasite and may contribute to chronic immunological memory. By mapping the pulmonary immunopeptidome, we identified a total of 57 unique peptides (peptides shared within both the mammalian and non-mammalian proteome) and one Ascaris-specific peptide, fragment of the RhoGEF protein Kalirin, that are sequestered within the pulmonary macrophage niche following resolution of Ascaris infection. The discovery that this single retained epitope maintains a persistent CD4+ T cell repertoire suggests that helminth-induced lung disease is not merely a consequence of initial mechanical and chemical tissue damage, but in addition, may manifest chronically by an antigen-driven process that continues long after parasite elimination. This mechanism provides a molecular explanation for the enduring pulmonary morbidity and systemic effects observed in mice even after resolution of infection and may provide an explanation to the high prevalence of non-smoking related chronic lung disease in low- and middle-income countries where Ascaris is endemic [16, 17]. In the standard model of pulmonary immunity to extracellular pathogens, antigens are internalized by phagocytes—predominantly pulmonary macrophages—and processed into epitopes for MHC class II presentation. Under normal conditions, this presentation is transient and should conclude shortly after the pathogen is eliminated to prevent chronic inflammation and immune-mediated tissue damage. However, our data show that the Ascaris-derived retained epitope persists within the lung chronically post-Ascaris larval clearance. The mechanisms allowing this specific Kalirin-derived retained epitope to bypass typical degradation pathways remain to be fully elucidated. It is possible that the unique structural properties of the Kalirin fragment confer resistance to lysosomal proteases, or that the specialized intracellular environment of pulmonary macrophages—particularly interstitial macrophages—acts as a protective niche [18, 19]. This sequestration could effectively convert a transient innate response into a chronic antigenic stimulus, providing a molecular basis for the persistent immunological remodeling of the lung following the resolution of the larval migration cycle. As shown in Fig 3, we have identified a distinct, rare population of CD4+ T cells reactive to the Kalirin-derived retained epitope. While the specific effector profile of these cells remains under investigation, their persistence months after infection resolution suggests they are central to the maintenance of immune-mediated chronic pulmonary diseases. In typical models of chronic antigen exposure, T cells often transition into an exhausted state characterized by the expression of inhibitory receptors like PD-1 or LAG-3 [20]. However, the progressive nature of the emphysema-like remodeling and vascular permeability observed in our model suggests these epitope-specific T cells may actually contribute to the chronically active and pathogenic environment. T helper cells are central coordinators of the host immune response to Ascaris larval migration. During the acute phase, the transit of larvae through the lung parenchyma incites a robust Type 2 (Th2) response characterized by the recruitment of eosinophils and the production of IL-4, IL-5, and IL-13, which collectively drive acute allergic airway disease and chronic lung pathologies [10, 12]. While this response is intended to constrain larval development, our data suggest that the persistent presence of the Kalirin-derived peptide maintains a specific CD4 + T cell repertoire long after the larvae have cleared. In typical helminth models, sustained type-2 signaling can transition from a wound-healing role into a driver of pathological tissue remodeling [12]. Specifically, these persistent T cells could promote the COPD-like phenotype through the sustained secretion of pro-inflammatory cytokines that recruit secondary effector cells and activate matrix-degrading enzymes. Chronic type-2 signaling is known to stimulate macrophages to release matrix metalloproteinases (MMPs) which can degrade the alveolar architecture and lead to the emphysematous changes as we have shown previously in the Ascaris murine model [12]. Furthermore, the localized activity of these T cells around the bronchovascular bundle may disrupt endothelial barrier integrity, providing a mechanistic link to the long-term vascular permeability and subsequent anemia observed in murine lungs months after Ascaris infection resolution [12]. The continuous stimulation provided by the retained epitope prevents the restoration of pulmonary homeostasis and transforms a transient larval migration into a driver of sustained pulmonary immune activation. The discovery of a retained Ascaris-specific epitope that persists after parasite clearance could have profound implications for global health strategies. Current World Health Organization guidelines rely heavily on Mass Drug Administration (MDA) using anthelmintic drugs like albendazole and mebendazole. However, these medication strategies primarily target the adult worm and lack significant efficacy against re-infection and migrating larvae. The larval transit through the lungs—and the subsequent deposition of the retained epitope—remains an unaddressed window of pathology. Our findings suggest that even a successfully treated infection can leave a reservoir of sequestered antigens that continue to fuel chronic pulmonary inflammation. Consequently, clinical management of ascariasis must evolve beyond simple parasite elimination from the infected host to include interventions that either prevent Ascaris infection or target the retained epitope within the specialized immune compartments. Future efforts should prioritize the development of therapies or vaccines designed to neutralize these retained molecular signals, thereby preventing the transition from a transient infection to life-long chronic respiratory disease. The identification of a specific, non-mammalian retained epitope derived from Kalirin offers a promising target for the development of the first preventative or therapeutic vaccine against Ascaris-induced pulmonary disease. In addition to previous vaccine efforts that have targeted preventing infection or reducing worm burden, an alternative strategy of vaccine development should evaluate if vaccination against the specific retained epitope could neutralize the “molecular legacy” of larval migration through the lungs. By priming the immune system to recognize and rapidly clear this peptide, such a vaccine could prevent its sequestration within the specialized macrophage niche and prevent long-term pulmonary morbidity. Unlike established vaccine candidates such as As14 or As16 [21], which target larval surface proteins to prevent infection or migration, the Kalirin-derived epitope offers a distinct therapeutic strategy. By targeting a sequestered signal responsible for chronic immune activation, such a vaccine could potentially treat individuals who have already been exposed, effectively neutralizing the persistent antigenic stimulus and preventing the transition to chronic respiratory disease. While we identified a total of 57 unique peptides (peptides shared within both the mammalian and non-mammalian proteome), only one peptide was Ascaris-specific and used for further downstream investigations. The detection of a single dominant Ascaris-specific peptide from Kalirin is unusual but may be influenced by the specific binding preferences of the BALB/c I-Ad MHC-II allele. Furthermore, our strict bioinformatic filtering—intended to minimize false positives—may have excluded other parasite specific peptides and those with significant homology to host proteins. Certainly, other peptides may play a role in long-term immune activiation, however, the identification of this single high-confidence epitope provides a robust starting point for evaluating the ‘molecular legacy’ of larval migration through the lungs. While we identified a single, dominant retained epitope from the protein Kalirin, it is also possible that other parasite-derived peptides persist that were lost during the peptide isolation and purification steps or exist at levels below the current limit of detection for LC-MS/MS. Future studies utilizing enrichment techniques may reveal additional components of the antigenic footprint left by migrating larvae. Our data localized the peptide within the specialized macrophage niche, but pulmonary macrophages represent a heterogeneous population consisting of distinct subsets such as alveolar and interstitial macrophages with distinct functions [12]. Given that interstitial macrophages occupy a niche closer to the BVB, they may play a more important role in long-term presentation of the epitope. Further investigation using single-cell proteomics or spatial transcriptomics is required to determine if a specific subset is uniquely responsible for the long-term sequestration of the Kalirin fragment. In addition, further studies on other macrophage-rich organs, such as lymph nodes or livers may reveal other long-term epitope reservoirs that serve as a nidus of on-going immune activation. We successfully identified a persistent CD4+ T cell population reactive to the Kalirin epitope. However, it is important to note that these epitope-specific T cells represent rare events, often occurring at frequencies of less than 0.1% of the total pulmonary CD4+ T cells. Consequently, the full transcriptomic and epigenetic profile of these cells remains to be elucidated. The low frequency of these Kalirin-reactive cells necessitated precise gating for identification in individual animals (n = 4); however, conducting a robust ‘deep-dive’ into lineage-specific (i.e., GATA3 for Th2 cells) or tissue-resident memory markers [22] would require large-scale pooling of animals for every individual biological replicate, which was outside the scope of this discovery-phase study. Determining the specific phenotype of these cells will be a critical objective for future investigations utilizing specialized enrichment or single-cell approaches. While our current findings demonstrate the persistence and immunogenicity of the Kalirin-derived epitope, several functional questions remain. Future studies involving the immunization of animals with the isolated peptide will be critical to evaluate its full potential as a vaccine candidate and its ability to modulate the host immune landscape. Furthermore, assessing the humoral response and antibody kinetics in relation to peptide sequestration may provide complementary insights into how the host maintains immune pressure over time. Finally, the discovery of this persistent epitope opens the door to reinfection models designed to investigate whether this ‘molecular legacy’ influences the dynamics of subsequent parasite exposures. Determining if the prolonged presence of the Kalirin fragment primes the lung for enhanced protection or exacerbated pathology will be essential for the development of targeted clinical interventions against chronic helminth-induced disease. In conclusion, our study identifies a specific Kalirin-derived retained epitope as a potential significant molecular contributor of chronic pulmonary pathology following Ascaris infection. Using immunopeptidomics, we demonstrated that this unique parasite signature is sequestered within the pulmonary macrophage compartment providing a persistent antigenic stimulus that maintains a may chronically active a pathogenic T cell repertoire. These findings establish that the long-term respiratory morbidity associated with ascariasis could be the result of an active, antigen-driven process that continues long after the physical elimination of the parasite. The discovery of this specific epitope reveals a prospective novel vaccine target capable of intercepting the persistent inflammatory signals that characterize the long-term legacy of larval migration. Ultimately, targeting the retained epitope offers a novel therapeutic pathway to decouple initial and repetitive larval exposure from life-long chronic respiratory disease and could represent a significant advancement in the clinical management of neglected tropical diseases. Methods Ethics statement All experimental protocols were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine (AN-9173) and followed federal guidelines. Mice. 8-week-old BALB/c female mice (wildtype) were purchased from Jackson Laboratories (cat: 000651). Upon arrival, mice were randomized into experimental groups (n = 4 per group for flow cytometry and histology; n = 10 mice pooled per replicate for immunopeptidomics). Only female mice were used to ensure consistency in immune responses and Ascaris suum infectious burden as previously described [12]. All mice were housed in a vivarium under specific-pathogen-free conditions. A. suum experimental murine model: A. suum eggs were obtained from adult female worms from infected pigs in the Weatherhead laboratory at Baylor College of Medicine. Briefly, adult female worms were isolated and dissected to remove the uterus. The uterus was then strained through a filter to release unembryonated eggs. The eggs were washed with PBS three times and subsequently resuspended in sulfuric acid (0.2N) for 60 days to allow for embryonation. For single infections, BALB/c mice were treated with a single inoculum of 2,500 embryonated A. suum eggs via oral gavage or PBS as previously described [8, 11, 23]. The dose of 2,500 A. suum eggs is a standardized inoculum used in murine models to successfully recapitulate the severe allergic airway disease and chronic remodeling observed in human and porcine infections [9, 11]. The A. suum larvae migratory cycle in a murine model mimics the life cycle in humans, albeit the larvae do not develop into adult worms in the murine model and are excreted in stool prior to development into adults worms, and has been previously described [10, 11]. Following oral gavage of A. suum eggs or PBS, mice were euthanized at 1 month post infection, and lungs and spleens were harvested in preparation for experiments described below. Single cell collection and preparation from mouse tissues: Lungs and spleens were harvested post euthanasia. Lungs were cut into small pieces and incubated in digestion buffer (2mg/ml collagenase (#LS004177, Worthington), 0.04mg/ml DNAse (#10104159001, Sigma) 1, 20% FBS in HBSS) for 1 h at 37°C after which they were deaggregated by pressing through a 40 μM nylon mesh and centrifuged at 400 x g for 5 minutes at 4°C. Alternatively, spleens were deaggregated by directly pressed through a 40 μM nylon mesh and centrifuged at 400 x g for 5 minutes at 4°C. Supernatants were discarded, and 1.5 mL of ACK (Thermofisher scientific, Waltham MA) was added and incubated for 3 min at room temperature for erythrocyte lysis. ACK was then neutralized with 7.5 mL of complete RPMI-1640 (Corning, NY), with 10% FBS and 1% Pen Strep, (Gibco, Waltham MA). The resulting single cell suspension was centrifuged and prepared for further analysis [24, 25]. Pulmonary macrophage isolation: Total pulmonary macrophages from lung single cell suspension were isolated using anti-F4/80 microbeads (cat: 130-110-443, Miltenyi Biotec) following the manufacturer’s protocol using LS columns (cat: 130-042-401, Miltenyi Biotec) and MidiMACS separator (cat 130-042-301, Miltenyi Biotec). For the discovery of retained epitopes, pulmonary macrophages were pooled from 10 infected mice to optimize peptide recovery and ensure sufficient coverage of the immunopeptidome. While the LC-MS/MS was conducted as a high-sensitivity discovery run, the resulting epitope signature was validated in subsequent independent experiments. Peptide-MHC-II complex purifications: A detailed protocol describing the purification of MHC-bound peptides for identification by mass spectrometry has been previously described by our laboratory [26]. Briefly, murine pulmonary macrophages were lysed in lysis buffer (1% octyl-β-D-glucopyranoside, 0.25% sodium deoxycholate, 1.25x complete protease inhibitor cocktail, 1 mM PMSF (phenylmethylsulfonyl fluoride), 0.2 mM iodoacetamide, 1 mM EDTA (ethylenediaminetetraacetic acid), 150 mM NaCl, and 20 mM Tris-HCl, pH 8.0) while rotating at 4 °C. After 1 hour, the lysate was centrifuged down for 10 min at 2,000 x g, and the supernatant was subsequently spun down again for 30 min at 16,000 x g at 4 °C. Soluble proteins in supernatant were removed from insoluble, pelleted fraction. To perform the immunoaffinity purification of the MHC-II peptides, peptide–MHC-II complexes in soluble lysate fraction were immunoprecipitated using 2.5 mg anti-mouse MHC-II (clone M5/114, cat. 14-5321-85, Thermofisher) monoclonal antibodies covalently linked to AminoLink Plus coupling resin (cat. 20501, Thermofisher). The lysate was rotated overnight at 4 °C with the resin. The following day, the resin containing peptide – MHC-II complexes was washed sequentially with 150 mM NaCl in 20 mM Tris pH 8.0, 400 mM NaCl in 20 mM Tris, pH 8.0 (high salt), 150 mM NaCl in 20 mM Tris pH 8.0, and finally 20 mM Tris pH 8.0 (no salt). Peptide–MHC-II complexes were finally eluted using 10% acetic acid. The eluent was further acidified by adding trifluoroacetic acid to a final concentration of 0.5% (v/v). To separate peptides from MHC molecules, a C18 resin cartridge (cat. 60108, Thermofisher) purification was conducted [27]. The C18 resin was activated with 100% acetonitrile containing 0.1% TFA and then pre-equilibrated with water containing 0.1% TFA. After loading the eluent onto the cartridge, peptides and proteins were allowed to bind, and the resin was washed with 100% water containing 0.1% TFA. Peptides were then eluted from the column using 25% acetonitrile containing 0.1% TFA, while larger proteins including MHC molecules remained bound. Purified peptides were dried overnight in a SpeedVac, and stored at −80 °C. Nano-LC-MS/MS analysis: Nano-LC-MS/MS analysis were carried out on dried purified peptide by Creative proteomics. Peptide Desalting and Preparation: Following immunoaffinity purification and elution, the peptide samples were desalted using ZipTip C18 columns (Millipore). Briefly, columns were activated with 100% acetonitrile (ACN) and equilibrated with 0.1% trifluoroacetic acid (TFA). Samples were loaded in 0.1% TFA, washed, and eluted in 60% ACN. The resulting eluates were lyophilized to near dryness and resuspended in 20μL of 0.1% formic acid (FA) for subsequent mass spectrometry analysis. Liquid Chromatography: Separation Peptide separation was performed on an Ultimate 3000 nano UHPLC system (Thermo Scientific). The system utilized a two-column setup: a PepMap C18 trapping column (100 Å, 100μm × 2 cm, 5μm) followed by a PepMap C18 analytical column (100 Å, 75μm × 50 cm, 2μm). Mobile phases consisted of 0.1% FA in water (Phase A) and 0.1% FA in ACN (Phase B). Peptides were separated at a flow rate of 250 nL/min using a multi-step linear gradient: 2% to 8% B over 5 min, 8% to 20% B over 60 min, and 20% to 40% B over 33 min. Mass spectrometry: Acquisition The UHPLC was coupled to an Orbitrap Q Exactive HF mass spectrometer equipped with a Nanospray Flex Ion Source. The instrument was operated in Data-Dependent Acquisition (DDA) mode using a Top 20 method. Full MS scans were acquired from 300-1650 m/z at a resolution of 60,000 (at 200 m/z) with an automatic gain control (AGC) target of 3e6. For MS/MS fragmentation, the resolution was set to 15,000 with a normalized collision energy (NCE) of 28%. The isolation window was maintained at 1.4 Th, and dynamic exclusion was set to 30 s to prevent redundant precursor sampling. Precursors with unassigned charges, or charge states of 1 or >6, were excluded from fragmentation. Raw data files are available via ProteomeXchange via the PRIDE partner repository with identifier PXD079009. LC-MS/MS data analysis: The raw mass spectrometry data were analyzed using FragPipe (v23.0) and MSFragger (v4.2) [28]. To identify MHC class II-restricted peptides, MS/MS spectra were searched against a combined database containing both host and parasite proteomes. These included the Mus musculus proteome (UniProtKB; accessed 2025/10/16) and the Ascaris suum proteome (UniProtKB; accessed 2025/10/16). Using these proteomes a single FASTA file was generated and decoys were added by Fragpipe prior to analysis. Furthermore, all Fragpipe parameters were set at default, including the FDR (false discovery rate) at 1%. Polyclonal antibody generation: A custom polyclonal antibody targeting the retained epitope (ETLLFTAVGRKPE) was generated by GenScript (Piscataway, NJ, USA). Briefly, rabbits were immunized with the synthetic peptide and the resulting antiserum was affinity-purified against the target antigen (ETLLFTAVGRKPE) to ensure high specificity. Polyclonal antibody avidity and specificity were verified by indirect ELISA against the immunizing peptide. According to manufacturer, the polyclonal antibody demonstrated an OD450 from 3.134 to 1.678 at 1:1000–1:512,000 while IgG control showed background at 0.050. Histopathology: Lung tissue from mice 1 month post infection was fixed in 10% neutral-buffered formalin solution, processed and embedded in paraffin. 5 μm sections were cut and immunohistochemistry was carried out. Briefly, slides were deparaffinized, then permeabilized using 0.2% Triton X 100 (X100, Sigma-Aldrich, St. Louis, MO). After that, antigen recovery was completed using Diva Decloaker (DV2004, Biocare Medical, Pacheco, CA), and peroxidase blocked using 3% hydrogen peroxide. Slides were then blocked using 5% bovine serum albumin (A0100-005, Gendepot, Baker, TX) for 1 hour at room temperature, and incubated with primary polyclonal antibody against retained epitope (ETLLFTAVGRKPE, see above) in I-Block solution (T2015, Thermofisher scientific, Waltham MA) overnight at 4 °C. Slides were then incubated and stained using ABC-HRP and DAB kit (PK-6200, SK-4100, Vector Laboratories, Newark, CA). Slides were then counterstained with hematoxylin, dehydrated and mounted [23]. Quantification for DAB staining was carried out via ImageJ (Fiji). MHC Class II tetramer synthesis: To identify CD4+ T cells specific for the retained epitope, custom ProT2 MHC Class II Tetramers were utilized (ProImmune, Oxford, UK). The tetramers were generated using H-2 IAd molecules loaded with the synthetic retained peptide. These MHC-peptide complexes were multimerized using R-Phycoerythrin (R-PE) conjugated streptavidin to ensure high-avidity binding to antigen-specific T cell receptors. Flow cytometry: Total lung cells and splenocytes isolated from mice 1 month post infection were stained for flow cytometry. Tissue processing and single cell suspension were described above. Briefly, MHC class II tetramers from above were centrifuged at 14000 × g for 5 minutes at 4°C, and stained the cells for 2 hours in the dark at 37 °C following the manufacturer’s protocol. After that, cells were stained with Live/Dead Fixable Violet (L34964, Thermofisher scientific, Waltham MA) and CD45 (103112, Biolegend, San Diego, CA). For T helper cell staining, cells were stained with CD3, CD4 (100222, 100412, Biolegend, San Diego, CA) [24, 25]. Flow cytometry was performed on an LSRII (BD Biosciences) and data were analyzed using FlowJo software (version 10.0.7; Treestar, Ashland, OR). Additional gating strategy is shown in S1 Fig. Statistical analysis: Data are presented as means ± standard errors of the means. Significant differences relative to PBS-challenged naïve mice are expressed by p values of <0.05, as measured two tailed Student’s t-test. Data normality was confirmed using the Shapiro-Wilk test. Experiments were repeated at least twice. All data points in the manuscript identify biological replicates. Supporting information Full list of all 57 identified peptides presented by pulmonary macrophages. (XLSX) Additional flow cytometry gating for pulmonary T cells. (EPS) 3 Apr 2026 -->PNTD-D-26-00331 Long-term retention of a single Ascaris epitope promotes chronic T cell activation post-clearance PLOS Neglected Tropical Diseases Dear Dr. Weatherhead, Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript within by Jun 02 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: * A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below. * A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. * An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. We look forward to receiving your revised manuscript. Kind regards, Bruce A. Rosa Academic Editor PLOS Neglected Tropical Diseases Krystyna Cwiklinski Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 Additional Editor Comments: Please carefully consider the reviewer feedback and revise the manuscript accordingly. In accordance with PLOS NTD guidelines, please provide any relevant animal study approval numbers in addition to the approving institution name already provided. Also, in accordance with PLOS NTD data availability guidelines, please ensure that the raw proteomics data is uploaded and accessible on a public repository, and provide access to processed data in a supplementary table. Additionally, please provide the supplementary figure as a PDF file, with a figure caption, for easier access to readers. Journal Requirements: 1) We do not publish any copyright or trademark symbols that usually accompany proprietary names, eg ©, ®, or TM (e.g. next to drug or reagent names). Therefore please remove all instances of trademark/copyright symbols throughout the text, including: - ® on page: 14. - TM on page: 12. 2) We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files after the references list. 3) Figure 1: Please confirm whether you drew the images / clip-art within the figure panels by hand. If you did not draw the images, please provide (a) a link to the source of the images or icons and their license / terms of use; or (b) written permission from the copyright holder to publish the images or icons under our CC BY 4.0 license. Alternatively, you may replace the images with open source alternatives. See these open source resources you may use to replace images / clip-art: - https://commons.wikimedia.org - https://openclipart.org/ Reviewers' Comments: Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: - Incomplete reporting of animal numbers: The manuscript does not specify the number of animals included. Although randomization into longitudinal groups is mentioned, only a single time point (1 month post-infection) is presented in the results. Clarification of group sizes and time points is necessary. And the dataset would greatly benefit from including multiple time points. - Missing ethical approval information: Animal study approval numbers are not provided. - Choice of female mice: The rationale for using female mice cites a previous/ and in this one rather unrelated publications on sex differences in asthma incidence. This does not justify sex-specific effects in A. suum infection or related to infectious burden? - Normality of sulfuric acid: The concentration used for egg embryonation is not specified. - Peptidomics sample clarification: The number of independent biological replicates and any technical replicates for LC‑MS/MS analysis are not stated. It is unclear whether lung cells were pooled or analyzed individually. Reviewer #2: The methodology presented in this study is clear even though complex for non-experienced readers. It is both solid and supported by clear background evidence. It highlights the use of mouse model to address the possibility of antigen retention that could lead interesting developments in the control of ascariasis. The methodology used in this study is clear, adequate and supports the objective of this study. Reviewer #3: (No Response) ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: Results - Major: - Lack of translational immunogenicity data: The immunogenic and retention potential of the identified peptide is not assessed, particularly in the context of MHCII haplotypes of natural hosts. This significantly limits translational interpretation. - Data availability: A complete list of all identified peptides per run, including host-derived peptides, should be made available to support reproducibility and community interest in e.g. host proteins, protein modification during retention. If peptides with mixed sequence identity were detected, it becomes even more critical to demonstrate a causal link between the identified epitope and chronic inflammation. - Longitudinal analysis: Were peptides assessed at multiple time points post-clearance? Longitudinal peptide detection is essential to distinguish true antigen persistence from delayed clearance, stochastic LC‑MS/MS detection, or secondary antigen release through ongoing tissue damage. - Tetramer+ cell characterization: What proportion of Tet+ cells falls within Th2 vs. non‑Th2 CD4 subsets? Among Th2 cytokine-producing / CD40L+ cells, what fraction is Tet+? More broadly: how are peptide-specific T cells phenotypically characterized? This refers also to TRM/EM/Eff markers: Without tissue-resident memory T‑cell marker analysis, the claim that retained peptides drive chronic lung inflammation is not supported. Correlating peptide persistence with T‑cell activation signatures would significantly strengthen the central claim. Minor: - Antibody specificity: Specificity of the polyclonal antibodies is insufficiently validated. No data using A. suum larval material are shown. - Quantitative histology: The strong, widespread staining pattern in the selected representative sections warrants quantification across different lung regions. - Tissue specificity of antigen retention: The manuscript does not address whether peptide retention is lung‑macrophage specific. - LC‑MS/MS sensitivity: The authors may consider optimizing MS detection sensitivity to enhance peptide coverage, especially given the presence of Tet+ T cells. - Macrophage heterogeneity: Given the distinct roles of alveolar vs. interstitial macrophages in antigen processing, the authors should address which population most likely presents the retained peptides. - Figure issues: Fig.2 IHC image quality: The resolution of immunohistochemistry images should be improved. Fig. 3A: x-axis label should read Tetramer. Fig. 3B: Interpretation as “Type 2 cells” is not supported, as no Th2-specific markers were included. Absolute cell counts require clarification (per lung, per lobe, per gram tissue). Reviewer #2: The results are clear, complete and easy to understand. The results are in line with proposed research question. Main article images are easy to understand. Struggled to open the supplementary file and could not analyse it properly. Reviewer #3: (No Response) ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: Based on the currently presented dataset, the main conclusions of the manuscript are only supported to a limited extent. Several key experimental components required to substantiate the proposed mechanism: such as a comprehensive characterization of peptide‑specific T cells, validation of antigen persistence across multiple tissues/cell niches/cells and time points —are missing or insufficiently resolved. As a result, direct evidence for a causal link between long‑term peptide retention and sustained T‑cell activation during chronic inflammation remains preliminary, and the central claims cannot yet be fully justified by the available results. The current title implies a causal relationship between a single retained epitope and chronic T‑cell activation. This relationship is currently not experimentally demonstrated. The title should be revised to avoid overstating causality. Discussion - Several claims in the discussion extend beyond what the data currently support and should be tempered (overinterpretation). As one example: The supposed “specialized macrophage niche” is not demonstrated; only one APC population was analyzed, without distinguishing macrophage subsets or comparing different tissues. - Infection dose and translational relevance: The unusually high infection dose should be discussed in the context of natural infections in pigs. It is unclear whether similar prolonged allergic responses occur in the natural host. - Unexpected detection of a single peptide: The detection of only one retained peptide is surprising. Potential explanations related to mouse genetics, antigen processing pathways, and not only MS sensitivity should be addressed. Reviewer #2: Conclusions are well presented and supported by the data. Authors clearly discuss how these findings could be useful in the context of Ascaris control and, therefore, its relevance in Public Health. The limitations of the study are well presented and adequate given the context. A couple of points that could be of interest should the authors consider them as so: - Could this retainment of the peptide be due to the model itself because of the inability of development of Ascaris adults? As clearance in this species is mainly in the lungs as well while we have some in the human intestine, could we expect a difference in the level of peptide in the lungs between mouse model and humans? - It is suggested that this peptide could maybe be an interesting target in vaccination development. Maybe it would be interesting to do a very brief comparison between this and other targets, regarding maybe location or parasite development stage? Reviewer #3: (No Response) ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: For peptide identification studies, I generally suggest that the raw MS data should be available in publicly accessible repositories. Reviewer #2: Address the appearance of DOI in references section (Wu 2024). Both the full and short title specifically mention epitope while in the end of introduction the authors mention peptide, followed by epitope, and then once again and interchange between peptide and epitope in the results section. Could this be evaluated to make it more coherent? Maybe peptide in the title could make it more appealing/understandable as well for the overall audience? Reviewer #3: (No Response) ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: The manuscript addresses a conceptually very interesting question. The identification of specific epitopes is of particular importance and may provide novel insights into the mechanisms underlying chronic T‑cell activation following helminth infection. The overall approach of the manuscript is methodologically sound, and the focuses on the identification as a first step in antigen retention. Tissue antigen depots, delayed antigen degradation, and potential cross-reactivity are only discussed, but might be a point for later studies. However, to me, the dataset appears preliminary, and the authors themselves acknowledge that several important aspects require further investigation. Based on the current level of evidence, it may be premature to support publication as a full research article; the work might be more suitable as a brief report at this stage or requires substantial major revisions. Please find my results related concerns as well as the requested additional experiments/data summarized in the Results section. Reviewer #2: The study presented aims to address the question of which Ascaris peptides are retained in the lungs and further reinduce inflammatory response. This study follows-up findings from Oliveira et al. 2024 that highlighted this situation but did not identify which specific peptides were responsible. Using mouse models the authors were able to identify one peptide that could be responsible for this. The implications on this are of great significance as this could be an important target for vaccine development that could not only act directly on larvae development but also reduce inflammatory response with further re-infections. The work is well written and clearly presenting both achievements and limitations. While there were just a few points that could improve, the work stands on its own merit as it is. Reviewer #3: The present study identified an Ascaris-specific peptide presented by MHC II on pulmonary macrophages even after larval migration through the lungs and the resolution of infection. The identification of this antigen at a persistent stage, one month after infection, represents a novel finding of considerable scientific relevance, particularly as it contributes to the understanding of the immunological mechanisms involved in disease chronicity and may provide insights into potential therapeutic targets. Although the manuscript is well written and concise, and the methodology is consistent with the proposed objectives, I would like to suggest some points for consideration: General comments • Some statements throughout the manuscript appear to overemphasize the findings. In particular, in the Author Summary and in the discussion, certain passages suggest that this mechanism is responsible for persistent inflammation, implying a direct cause-and-effect relationship. However, it is well established that immune responses to helminths are multifactorial, and antigen persistence may be associated not only with sustained immune activation but also with immune modulation or regulatory processes. Therefore, the prolonged presence of this antigen should be interpreted as a potential contributing factor rather than the direct causal mechanism of persistent inflammation. Methodology • I suggest increasing the experimental sample size, considering that animal model studies typically present biological variability. A sample size of four animals may limit the robustness of the analyses and restrict stronger interpretations of the results. • In the section Nano-LC-MS/MS Analysis, the word “Briefly” at the beginning of the sentence appears redundant and could be removed. • In the flow cytometry section, it would be helpful to indicate that the description of tissue processing for this technique was already presented in a previous section (Single cell collection and preparation from mouse tissues), which may facilitate understanding. Results and discussion • Based on the methodology employed, the authors were able to identify the antigen, detect its presence in the lung parenchyma, and analyze the increase in lymphocyte populations over the investigated period. However, based on the markers used in the flow cytometry analysis, it is only possible to conclude that there is an increase in CD4⁺ T lymphocytes. No lineage-specific markers were included to characterize T helper cell subsets, such as GATA3 for Th2 cells. Furthermore, it is not possible to determine whether this expanded population is functionally activated. To support such an interpretation, activation markers such as CD25, CD69, or CD44 would be necessary. • With the data currently presented, it is still difficult to determine how the presence of this antigen is effectively influencing the host immune response. To strengthen these interpretations, additional experiments could be considered alongside the current approach. For instance, immunization of animals with the isolated antigen followed by immunological analyses could help evaluate its immunogenic potential. In addition, assessing the humoral response throughout the course of infection could contribute to a better understanding of the immune dynamics associated with antigen persistence. In this context, measuring antibody levels at different time points during infection and after its resolution could provide complementary information on the maintenance of immune responses over time. Another possibility would be to perform a reinfection model to investigate whether the prolonged presence of this antigen influences the dynamics of subsequent infections. • Figure 3A: Is the observed profile homogeneous among the four animals analyzed? It would be helpful to include the mean and standard deviation of the gating percentages, which could facilitate interpretation of the data. • Figure 3B: In the legend, A. suum should be written in italics. • In the Discussion, in the sentence beginning with “In typical models of chronic antigen exposure…”, a reference should be included at the end of the statement. • Additionally, the discussion could be strengthened by including a brief overview of the role of T helper cells in Ascaris infection, particularly considering that this cell population was evaluated in the flow cytometry analyses. Overall, the study presents an original and relevant finding that contributes to the understanding of the immune response associated with Ascaris infection. The suggestions provided aim to strengthen the interpretation of the results and to better contextualize the findings within the existing literature. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] Figure resubmission: --> -->-->While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.-->--> After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.--> Reproducibility: To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols --> 13 Apr 2026 Submitted filename: 2026 PLOS NTD response to reviewer 04-09-26_JWedits.docx 22 May 2026 -->PNTD-D-26-00331R1-->-->Identification of a persistent Ascaris-derived Kalirin epitope associated with chronic T cell activation in the lung-->-->PLOS Neglected Tropical Diseases-->-->Dear Dr. Weatherhead,-->-->Thank you for submitting your manuscript to PLOS Neglected Tropical Diseases. After careful consideration, we feel that it has merit but does not fully meet PLOS Neglected Tropical Diseases's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.-->-->Please submit your revised manuscript by Jun 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosntds@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pntd/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.-->-->Please include the following items when submitting your revised manuscript:-->-->* A letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. This file does not need to include responses to any formatting updates and technical items listed in the 'Journal Requirements' section below.-->-->* A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.-->-->* An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.-->-->If you would like to make changes to your financial disclosure, competing interests statement, or data availability statement, please make these updates within the submission form at the time of resubmission. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.-->-->As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors.-->-->We look forward to receiving your revised manuscript.-->-->Kind regards,-->-->Bruce A. Rosa-->-->Academic Editor-->-->PLOS Neglected Tropical Diseases-->-->Krystyna Cwiklinski-->-->Section Editor-->-->PLOS Neglected Tropical Diseases-->--> Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 -->-->Additional Editor Comments: -->-->We have received feedback on the revision from two of the reviewers, who have suggested some additional minor revisions to be considered. Additionally, in accordance with Reviewer 1's suggestion, please ensure that the raw MS proteomics datasets are uploaded to an appropriate repository, and provide accession information in the next resubmission, as this is required by PLOS NTD Data Availability requirements. If you do not want to make the data immediately public, then a reviewer link should be provided so that it can be verified.-->-->Reviewers' comments: -->-->Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #2: (No Response) Reviewer #3: (No Response) ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #2: (No Response) Reviewer #3: (No Response) ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #2: (No Response) Reviewer #3: (No Response) ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #2: The sentence i the begining of the methods "The dose of 2,500 A. suum eggs (...)" is in italic and should be changed. Small typo in the begining of the discussion with "may contributes". Should be changed to "may contribute". Mention where raw MS data will be available. Reviewer #3: The authors have carefully addressed the points raised in the previous review, responded thoughtfully to the comments, and made modifications to the manuscript in accordance with the suggestions provided. At this stage, I only have minor observations related to spelling and font/style consistency: Discussion section At the beginning of paragraph 10, the word while appears in a different font from the rest of the text. In the final sentence of paragraph 11, there are two periods and this should be corrected. Methods section In the A. suum experimental murine model subsection, the sentence “The dose of 2,500 A. suum eggs is a standardized inoculum used in murine models to successfully recapitulate the severe allergic airway disease and chronic remodeling observed in human and porcine infections” appears in a different font from the rest of the text. In the Peptide-MHC-II complex purifications subsection, please correct the spelling/formatting of 1.25x cOmplete. ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #2: The changes made to the manuscript based on the suggestions by the others reviewers improved the overall quality of the paper. I want to commend both the other reviewers for their suggestions and the authors for accurately addressing them. Reviewer #3: (No Response) ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No Reviewer #3: No -->-->[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]-->-->Figure resubmission: -->-->-->While revising your submission, we strongly recommend that you use PLOS’s NAAS tool (https://ngplosjournals.pagemajik.ai/artanalysis) to test your figure files. NAAS can convert your figure files to the TIFF file type and meet basic requirements (such as print size, resolution), or provide you with a report on issues that do not meet our requirements and that NAAS cannot fix.-->--> After uploading your figures to PLOS’s NAAS tool - https://ngplosjournals.pagemajik.ai/artanalysis, NAAS will process the files provided and display the results in the "Uploaded Files" section of the page as the processing is complete. If the uploaded figures meet our requirements (or NAAS is able to fix the files to meet our requirements), the figure will be marked as "fixed" above. If NAAS is unable to fix the files, a red "failed" label will appear above. When NAAS has confirmed that the figure files meet our requirements, please download the file via the download option, and include these NAAS processed figure files when submitting your revised manuscript.-->-->-->Reproducibility: -->-->To enhance the reproducibility of your results, we recommend that authors of applicable studies deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols--> 1 Jun 2026 Submitted filename: 2026 PLOS NTD response to reviewer 05-29-26.docx 2 Jun 2026 Dear Dr. Weatherhead, We are pleased to inform you that your manuscript 'Identification of a persistent Ascaris-derived Kalirin epitope associated with chronic T cell activation in the lung' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Bruce A. Rosa Academic Editor PLOS Neglected Tropical Diseases Krystyna Cwiklinski Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** The authors have addressed all reviewer concerns p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; line-height: 16.0px; font: 14.0px Arial; color: #323333; -webkit-text-stroke: #323333}span.s1 {font-kerning: none Dear Dr. Weatherhead, We are delighted to inform you that your manuscript, "Identification of a persistent Ascaris-derived Kalirin epitope associated with chronic T cell activation in the lung," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. For Research Articles, you will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases